Chronic erythropoietin treatment decreases post-infarct myocardial damage in rats without venous thrombogenic effect

Cardiology

Volumn 112, Issue 2, 2009, Pages 129-134

  Prunier, F ^a,d   Pottier, P ^a,b   Clairand, R ^a   Mercier, A ^a   Hajjar, R J ^c   Planchon, B ^b   Furber, A ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITÉ D'ANGERS   (France)

Author keywords

Cardioprotection; Erythropoietin; Myocardial infarction; Thrombosis

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEMATOCRIT; INFERIOR CAVA VEIN; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; THROMBOGENICITY; VEIN THROMBOSIS;

EID: 58149087248     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000142723     Document Type: Article

References (23)

1. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-4806.
2. Joyeux-Faure M, Godin-Ribuot D, Ribuot C: Erythropoietin and myocardial protection: what's new? Fundam Clin Pharmacol 2005;19:439-446.
3. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI: Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003;100:11612-11617.
4. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI: Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 2005;19:243-250.
5. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ: Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 2004;279:20655-29662.
6. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS: A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
7. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ: Erythropoietin in cardiovascular diseases. Eur Heart J 2004;25:285-291.
8. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL: Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003;108:79-85.
9. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG: Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 2004;44:473-479.
10. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N: Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003;308:990-994.
11. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG: Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125-133.
12. Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, Hajjar RJ: Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2007;292:H522-H529.
13. Taylor JE, McLaren M, Henderson IS, Belch JJ, Stewart WK: Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant 1992;7:235-239.
14. Taylor JE, Belch JJ, McLaren M, Henderson IS, Stewart WK: Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kidney Int 1993;44:182-190.
15. Wolf RF, Peng J, Friese P, Gilmore LS, Burstein SA, Dale GL: Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb Haemost 1997;78:1505-1509.
16. Biesma DH, Bronkhorst PJ, de Groot PG, van de Wiel A, Kraaijenhagen RJ, Marx JJ: The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors. J Lab Clin Med 1994;124:42-47.
17. Malyszko J, Malyszko JS, Borawski J, Rydzewski A, Kalinowski M, Azzadin A, Mysliwiec M, Buczko W: A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 1995;77:133-143.
18. Viron B, Jaar B, Verdy E, Mignon F: Erythropoietin-induced protein S deficiency and vena cava thrombosis. Nephrol Dial Transplant 1992;7:979.
19. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714.
20. Pottier P, Planchon B, Truchaud F, Leftheriotis G, Herbert JM, Bressolette L, Trewick D, Passuti N: Development of an experimental model of pre-thrombosis in rats based on Wessler's principle using a calibrated venous stasis. Blood Coagul Fibrinolysis 2003;14:3-9.
21. Pottier P, Planchon B, Truchaud F, Leftheriotis G, Herbert JM, Bressollette L, Passuti N: Efficacy of pentasaccharide on a prethrombosis model based on a calibrated stasis by the increase in up-stream venous pressure. Blood Coagul Fibrinolysis 2003;14:587-591.
22. Rafiee P, Shi Y, Su J, Pritchard KA Jr, Tweddell JS, Baker JE: Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 2005;100:187-197.
23. Wald MR, Borda ES, Sterin-Borda L: Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J Cell Physiol 1996;167:461-468.